Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815825 · ClinicalTrials.gov registry record · Phase 2
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
NCT03815825 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 332 participants.
The verdict
NCT03815825, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
Study Summary
Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).
Interventions
- DRUG Placebo
- DRUG IONIS-FB-LRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815825
The ClinicalTrials.gov registry entry for NCT03815825 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03815825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03815825 about?
NCT03815825 is a clinical study titled "GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)". Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).
What is the current status of trial NCT03815825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2019-03-04. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT03815825?
The interventions under investigation include: Placebo (DRUG), IONIS-FB-LRx (DRUG).
Who is sponsoring clinical trial NCT03815825?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.